---
document_datetime: 2025-01-06 15:31:47
document_pages: 3
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/opdualag-epar-procedural-steps-taken-scientific-information-after-authorisation-archive_en.pdf
document_name: opdualag-epar-procedural-steps-taken-scientific-information-after-authorisation-archive_en.pdf
version: success
processing_time: 2.1179461
conversion_datetime: 2025-12-31 03:21:32.958488
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## Opdualag

Procedural steps taken and scientific information after the authorisation

| Application number   | Scope                                                                                                   | Opinion/ Notification 1 issued on   | Commission Decision Issued 2 / amended on   | Product Information affected 3   | Summary                                                                                                                                    |
|----------------------|---------------------------------------------------------------------------------------------------------|-------------------------------------|---------------------------------------------|----------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------|
| PSUSA/11018 /202403  | Periodic Safety Update EU Single assessment - nivolumab / relatlimab                                    | 17/10/2024                          | 12/12/2024                                  | SmPC and PL                      | Refer to Scientific conclusions and grounds recommending the variation to terms of the Marketing Authorisation(s)' for PSUSA/11018/202403. |
| II/0009/G            | This was an application for a group of variations. B.I.a.1.k - Change in the manufacturer of AS or of a | 05/09/2024                          | n/a                                         |                                  |                                                                                                                                            |

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

|                     | storage site of MCB and/or WCB B.I.a.1.f - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - Changes to quality control testing arrangements for the AS -replacement or addition of a site where batch control/testing takes place B.I.a.1.e - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - The change relates to a biological AS or a starting material [-] used in the manufacture of a biological/immunological product   |            |            |             |                                   |
|---------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-------------|-----------------------------------|
| IAIN/0010/G         | This was an application for a group of variations. C.I.z - Changes (Safety/Efficacy) of Human and Veterinary Medicinal Products - Other variation C.I.z - Changes (Safety/Efficacy) of Human and Veterinary Medicinal Products - Other variation A.6 - Administrative change - Change in ATC Code/ATC Vet Code                                                                                                                                                                                                  | 20/06/2024 | 12/12/2024 | SmPC and PL |                                   |
| PSUSA/11018 /202309 | Periodic Safety Update EU Single assessment - nivolumab / relatlimab                                                                                                                                                                                                                                                                                                                                                                                                                                            | 11/04/2024 | n/a        |             | PRAC Recommendation - maintenance |
| IB/0007             | B.I.b.1.z - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Other variation                                                                                                                                                                                                                                                                                                                                                                             | 09/02/2024 | n/a        |             |                                   |
| IB/0006             | B.I.d.1.a.4 - Stability of AS - Change in the re-test period/storage period - Extension or introduction of a re-test period/storage period supported by real time                                                                                                                                                                                                                                                                                                                                               | 08/01/2024 | n/a        |             |                                   |

<div style=\"page-break-after: always\"></div>

|                     | data                                                                                                                                                                                                                                                                                                                                                                                                                                       |            |            |    |                                   |
|---------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|----|-----------------------------------|
| N/0004              | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)                                                                                                                                                                                                                                                                                                                                           | 15/11/2023 | 12/12/2024 | PL |                                   |
| PSUSA/11018 /202303 | Periodic Safety Update EU Single assessment - nivolumab / relatlimab                                                                                                                                                                                                                                                                                                                                                                       | 26/10/2023 | n/a        |    | PRAC Recommendation - maintenance |
| IA/0002/G           | This was an application for a group of variations. B.II.e.7.b - Change in supplier of packaging components or devices (when mentioned in the dossier) - Replacement or addition of a supplier A.4 - Administrative change - Change in the name and/or address of a manufacturer or an ASMF holder or supplier of the AS, starting material, reagent or intermediate used in the manufacture of the AS or manufacturer of a novel excipient | 15/05/2023 | n/a        |    |                                   |
| IB/0001/G           | This was an application for a group of variations. B.II.d.1.d - Change in the specification parameters and/or limits of the finished product - Deletion of a non-significant specification parameter A.7 - Administrative change - Deletion of manufacturing sites B.II.d.2.d - Change in test procedure for the finished product - Other changes to a test procedure (including replacement or addition)                                  | 06/03/2023 | n/a        |    |                                   |